Literature DB >> 17868958

HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.

Cindy M P Duke1, Casey A Maguire, Michael C Keefer, Howard J Federoff, William J Bowers, Stephen Dewhurst.   

Abstract

HSV-1 amplicon vectors elicit strong T-cell responses to encoded antigens but the qualitative nature of these responses is poorly understood. Antigen-specific CD4(+) and CD8(+) T-cell responses to amplicon and adenovirus (rAd5) vectors encoding HIV-1 gp120 were assessed following immunization of mice, by performing intracellular cytokine staining for IFNgamma, IL2 and TNFalpha, following stimulation of splenocytes with a HIV-1 Env peptide pool. The quality of the primary T-cell response to amplicon and rAd5 vectors was strikingly similar, but there were qualitative differences in responses to amplicon vectors that incorporated different promoters upstream of gp120 - suggesting that promoters can significantly influence immune response quality. When prime-boost combinations were studied, a rAd5 prime and amplicon boost elicited the highest T-cell response. Furthermore, protocols that incorporated a rAd5 prime consistently elicited a greater proportion of polyfunctional CD4(+) T-cells-regardless of boost. This suggests that initial priming can shape immune response quality after a boost. Overall, these findings provide insight into effective vector combinations for HIV-1 vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868958      PMCID: PMC2092414          DOI: 10.1016/j.vaccine.2007.08.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  67 in total

1.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

2.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Amplicons as vaccine vectors.

Authors:  Kathlyn Santos; Cindy M P Duke; Stephen Dewhurst
Journal:  Curr Gene Ther       Date:  2006-06       Impact factor: 4.391

Review 4.  Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases.

Authors:  Giuseppe Pantaleo; Alexandre Harari
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

5.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 6.  Functional signatures of protective antiviral T-cell immunity in human virus infections.

Authors:  Alexandre Harari; Valérie Dutoit; Cristina Cellerai; Pierre-Alexandre Bart; Renaud A Du Pasquier; Giuseppe Pantaleo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

7.  A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

9.  Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.

Authors:  Beatrice O Ondondo; Hongbing Yang; Tao Dong; Kati di Gleria; Annie Suttill; Christopher Conlon; Denise Brown; Patricia Williams; Sarah L Rowland-Jones; Tomás Hanke; Andrew J McMichael; Lucy Dorrell
Journal:  Eur J Immunol       Date:  2006-10       Impact factor: 5.532

10.  Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge.

Authors:  Joseph J Mattapallil; Daniel C Douek; Alicia Buckler-White; David Montefiori; Norman L Letvin; Gary J Nabel; Mario Roederer
Journal:  J Exp Med       Date:  2006-05-30       Impact factor: 14.307

View more
  2 in total

1.  Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Authors:  William Domm; Lauren Brooks; Hung Li Chung; Changyong Feng; William J Bowers; Gene Watson; James L McGrath; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

2.  Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.

Authors:  José R Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Jonatan Ersching; Cibele A Tararam; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.